Heart attack survivors may benefit from diabetes drug, study finds
NCT ID NCT06903754
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 32 times
Summary
This study looked at whether a daily pill called an SGLT2 inhibitor (dapagliflozin or empagliflozin) can help people without diabetes who had a heart attack and a procedure to open blocked arteries. The goal was to see if the drug lowers the chance of being hospitalized for heart failure, having another heart attack, or dying. About 450 patients took part, and the results may offer a new way to protect the heart after a heart attack.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mohammed VI university hospital oujda
OUDA, Morocco
Conditions
Explore the condition pages connected to this study.